Influence of Air Quality on the Development and Progression of Premature Coronary Artery Disease (NCT06464042) | Clinical Trial Compass
UnknownNot Applicable
Influence of Air Quality on the Development and Progression of Premature Coronary Artery Disease
Spain4,272 participantsStarted 2024-05-23
Plain-language summary
The new global guidelines from the World Health Organization on air quality provide evidence of the damage that air pollution inflicts on human health at even lower concentrations than previously thought. Different studies have shown an increase in the incidence of coronary artery disease (CAD) in young people in recent decades. The main objective of this project is to study the impact of environmental pollutants on the premature manifestation of CAD from different epidemiological approaches and their impact on the evolution of these patients with a gender perspective. It is a retrospective analytical case-control study nested in a cohort of patients ≤40 years old with a clinical history of CAD including: ST-segment elevation myocardial infarction, non-ST-segment elevation acute coronary syndrome, unstable angina, stable angina or silent angina according to the international classification of diseases.
Who can participate
Age range
18 Years – 40 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
CASES:
Inclusion Criteria:
* Women and men between 18 and 40 years old with a diagnosis of coronary artery disease coded in their medical records in Galicia
Exclusion Criteria:
* Not having a postal code and primary care center assigned in their medical records in Galicia
CONTROL
Inclusion Criteria:
* Women and men between 18 and 40 years old with no diagnosis or history of CAD or other coronary disease coded in their medical records
Exclusion Criteria:
* Present with non-ischemic coronary diseas.
* Have a serious condition that affects or decreases life expectancy.
* Do not have a postal code or primary care center assigned in their medical records in Galicia
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
To determine the differences in exposure to environmental pollutants in patients ≤40 years old with and without coronary artery disease
Timeframe: 15 years
2
To evaluate the impact of environmental pollutants on the incidence of the combined variable of major adverse cardiovascular events (MACE) up to 1, 5, and 10 years from the index cas
Timeframe: 15 years
3
To describe the prevalence of CAD in patients ≤40 years old in Galicia